Avidity Biosciences Inc’s recently made public that its CSTO Flanagan W. Michael unloaded Company’s shares for reported $0.42 million on Dec 18 ’24. In the deal valued at $32.66 per share,12,742 shares were sold. As a result of this transaction, Flanagan W. Michael now holds 72,647 shares worth roughly $2.14 million.
Then, MacLean Michael F sold 11,151 shares, generating $364,192 in total proceeds. Upon selling the shares at $32.66, the Chief Financial Officer now owns 82,942 shares.
Before that, Boyce Sarah sold 31,855 shares. Avidity Biosciences Inc shares valued at $1,040,384 were divested by the President and CEO at a price of $32.66 per share. As a result of the transaction, Boyce Sarah now holds 265,308 shares, worth roughly $7.82 million.
H.C. Wainwright initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on December 20, 2024; the price target was $72. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late November with a ‘”an Outperform”‘ rating. Goldman began covering RNA with “Buy” recommendation on September 24, 2024. Barclays started covering the stock on August 28, 2024. It rated RNA as “an Overweight”.
Price Performance Review of RNA
On Friday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -1.57% to $29.46. Over the last five days, the stock has lost -5.52%. Avidity Biosciences Inc shares have risen nearly 1.31% since the year began. Nevertheless, the stocks have risen 157.07% over the past one year. While a 52-week high of $56.00 was reached on 01/06/25, a 52-week low of $9.93 was recorded on 01/10/25. SMA at 50 days reached $38.49, while 200 days put it at $37.59.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 28.46, which if violated will result in even more drops to 27.46. On the upside, there is a resistance level at 30.76. A further resistance level may holdings at 32.06. The Relative Strength Index (RSI) on the 14-day chart is 33.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.55%. Stochastics %K at 27.20% indicates the stock is a holding.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2024-12-13, growing by 0.96 million shares to a total of 15.48 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 14.52 million shares. There was a rise of 6.2%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 03, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
